New York, March 26, 2007 — LAWFUEL – Law Firm News – Kaye Scholer represented Novartis in an agreement with Bayer Schering Pharma AG that will provide Novartis the opportunity to introduce its own branded version of interferon beta-1b for patients with the debilitating neurological disease multiple sclerosis (MS). Bayer Schering Pharma will provide regulatory support and supply this medicine to Novartis in return for royalty payments. In addition, Novartis will transfer manufacturing responsibility for interferon beta-1b to Bayer Schering Pharma, which will purchase the related equipment and inventory as well as lease certain buildings at a Novartis site in Emeryville, California.
The Kaye Scholer team included partners Adam Golden and William Wallace, counsel Albert Pailet and associate Julia Haddad.
About Kaye Scholer
Kaye Scholer refers to Kaye Scholer LLP and its affiliates, with offices in New York, Chicago, Frankfurt, London, Los Angeles, Shanghai, Washington, D.C. and West Palm Beach. Founded in New York City in 1917, Kaye Scholer now includes some 525 attorneys and represents public and private companies, governmental entities, financial institutions and other organizations in matters around the world. Additional information is available on the firm’s website: www.kayescholer.com.
